satralizumab sold brand name enspryng humanized monoclonal antibody medication used treatment neuromyelitis optica spectrum disorder nmosd rare autoimmune drug developed chugai pharmaceutical subsidiary common side effects include common cold nasopharyngitis headache upper respiratory tract infection inflammation lining stomach rash joint pain extremity pain fatigue satralizumab regulates inflammation inhibiting receptor key mediator immune satralizumab approved medical use united states august european union june us food drug administration fda considers firstinclass satralizumab indicated treatment neuromyelitis optica spectrum disorder nmosd adults particular antibody people nmosd rare autoimmune disease central nervous system mainly affects optic nerves spinal people nmosd bodys immune system mistakenly attacks healthy cells proteins body often optic nerves spinal individuals nmosd typically attacks optic neuritis causes eye pain vision approximately people nmosd permanent visual impairment paralysis caused nmosd estimates vary nmosd thought impact approximately nmosd associated antibodies bind protein called binding antibody appears activate components immune system causing inflammation damage central nervous vaccination liveattenuated live vaccines recommended treatment administered least four weeks starting common side effects observed common cold nasopharyngitis headache upper respiratory tract infection inflammation lining stomach rash joint pain extremity pain fatigue fda label satralizumab includes warning increased risk infection including serious potentially fatal infections potential reactivation hepatitis b warnings precautions satralizumab include elevated liver enzymes decreased neutrophil counts hypersensitivity satralizumab humanized monoclonal antibody binds soluble membranebound human receptors thereby prevents signal transmission pleiotropic cytokine produced large number cell types involved variety inflammatory processes patients nmo nmosd elevated levels cerebrospinal fluid serum periods active proinflammatory processes involved nmosd thought involve including formation pathological autoantibodies permeability bloodbrain barrier mediators effectiveness safety satralizumab treatment neuromyelitis optica spectrum disorder nmosd demonstrated two clinical study satralizumab monotherapy included adult participants antibodies ie study treatment satralizumab reduced number nmosd relapses participants positive compared treatment placebo inactive study satralizumab adjuvant immunosuppressant treatment included adult participants immunosuppressant treatment combination satralizumab reduced rate relapses participants positive fourfifths compared immunosuppressant treatment fda approved satralizumab based evidence two clinical trials trial trial participants nmosd antibody trials conducted sites united states canada europe participants received random either satralizumab placebo injections according neither participants healthcare providers knew treatment second trial participants also receiving current immunosuppressive medications treatment benefit satralizumab evaluated measuring time first attack comparing evidence benefit participants antibody negative either satralizumab approved treatment nmosd canada japan satralizumab approved medical use united states august fda granted application satralizumab fast track orphan drug fda granted approval enspryng genentech satralizumab third approved treatment nmosd united fda considers satralizumab firstinclass satralizumab approved medical use european union june satralizumab international nonproprietary name united states adopted name immune activation dostarlimab ibalizumab httpsenwikipediaorgwikisatralizumab